Patents by Inventor Hugo Soares

Hugo Soares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC NANOBODIES
    Publication number: 20220242958
    Abstract: The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.
    Type: Application
    Filed: December 2, 2021
    Publication date: August 4, 2022
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Catelijne Stortelers, Peter Vanlandschoot, Stephanie Staelens, Miguel Conde, Hugo Soares, Dominique Schols
  • METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GYANYLYL CYCLASE (SGC)
    Publication number: 20220128561
    Abstract: The present invention provides a method for determining whether a human or animal subject suffers from oxidative stress, is suitable of being treated with an antioxidant and/or free radical scavenger, and/or is suitable of being treated with an agonist of soluble Guanylyl Cyclase (sGC), in particular with an activator of sGC, said method comprising the steps of providing a tissue or liquid sample from said subject, and determining whether or not said sample is characterized by the presence, upregulation or overexpression of sGC comprising a heme free ?1 subunit.
    Type: Application
    Filed: January 16, 2020
    Publication date: April 28, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Rene Hoet, Peter Sandner, Jan Robert Krähling, Agnes Benardeau, Ana Lúcia Freitas de Mesquita Barbas, Ligia Nobre, Hugo Soares, Gabriela Silva
  • Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
    Patent number: 11046773
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 29, 2021
    Assignee: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • BISPECIFIC CXCR4-CD4 POLYPEPTIDES WITH POTENT ANTI-HIV ACTIVITY
    Publication number: 20190292267
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 26, 2019
    Applicant: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
    Patent number: 10273305
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • BISPECIFIC CXCR4-CD4 POLYPEPTIDES WITH POTENT ANTI-HIV ACTIVITY
    Publication number: 20180086837
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 29, 2018
    Applicant: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • BISPECIFIC NANOBODIES
    Publication number: 20160251440
    Abstract: The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: September 1, 2016
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Catelijne Stortelers, Peter Vanlandschoot, Stephanie Staelens, Miguel Conde, Hugo Soares, Dominique Schols